Uroplasty announced that Humana, Inc. has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via its Urgent PC Neuromodulation System.
Uroplasty announced that Humana, Inc. has written a positive coverage policy for percutaneous tibial nerve stimulation (PTNS) delivered via its Urgent PC Neuromodulation System.
Humana is the sixth largest private insurer in the United States, with approximately 8.9 million covered lives in 35 states, and is also the administrator for Tricare South and several Medicare Advantage plans.
Urgent PC is an office-based, minimally invasive treatment for overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.
“This decision will now provide more patients access to the benefits of this clinically and cost-effective therapy,” said Darin Hammers of Uroplasty.
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC
December 5th 2023The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Malpractice Consult: What to know about direct examination of expert witnesses
December 4th 2023"In the 21st century, expert witnesses serve a vital role in presenting evidence to a jury. A good expert will be able to distill complex information into digestible elements the jurors can understand," writes Austin Richards, Esq.